WallStreetZenWallStreetZen

NASDAQ: SLRX
Salarius Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their SLRX stock forecasts and price targets.

Forecast return on equity

Is SLRX forecast to generate an efficient return?

Company
N/A
Industry
13.99%
Market
331.19%

Forecast return on assets

Is SLRX forecast to generate an efficient return on assets?

Company
N/A
Industry
12.6%

SLRX earnings per share forecast

What is SLRX's earnings per share in the next 1 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$9.35

SLRX revenue forecast

What is SLRX's revenue in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$12.1M

SLRX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
SLRX$0.65N/AN/A
AIM$1.34$22.00+1,541.79%Buy
INDP$2.14N/AN/A
ARTL$1.82$18.00+889.01%Strong Buy
ENSC$1.13N/AN/A
View Top Biotech Stocks

Salarius Pharmaceuticals Stock Forecast FAQ

What is SLRX's earnings growth forecast for 2025-2025?

(NASDAQ: SLRX) Salarius Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 204.1%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 3,004.99%.

Salarius Pharmaceuticals's earnings in 2025 is -$5,004,758.

In 2025, SLRX is forecast to generate -$54,831,296 in earnings, with the lowest earnings forecast at -$52,681,049 and the highest earnings forecast at -$56,443,981.

If you're new to stock investing, here's how to buy Salarius Pharmaceuticals stock.

What is SLRX's revenue growth forecast for 2025-2026?

(NASDAQ: SLRX) Salarius Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 9,640.01%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 1,452.58%.

Salarius Pharmaceuticals's revenue in 2025 is $0.On average, 3 Wall Street analysts forecast SLRX's revenue for 2025 to be $0, with the lowest SLRX revenue forecast at $0, and the highest SLRX revenue forecast at $0.

In 2026, SLRX is forecast to generate $71,008,562 in revenue, with the lowest revenue forecast at $68,224,028 and the highest revenue forecast at $73,095,497.

What is SLRX's forecast return on assets (ROA) for 2025-2026?

(NASDAQ: SLRX) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 12.6%.

What is SLRX's Earnings Per Share (EPS) forecast for 2025-2025?

(NASDAQ: SLRX) Salarius Pharmaceuticals's current Earnings Per Share (EPS) is -$33.91. In 2025, SLRX's EPS is forecast to hit -$9.35 (min: -$8.99, max: -$9.63).

What is SLRX's forecast return on equity (ROE) for 2025-2026?

(NASDAQ: SLRX) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.